

Title (en)  
COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION

Title (de)  
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR MODULATION DER TAU-GENEXPRESSION

Title (fr)  
COMPOSITIONS ET PROCÉDÉS DESTINÉS À MODULER L'EXPRESSION DE TAU

Publication  
**EP 2971142 B1 20200624 (EN)**

Application  
**EP 14767904 A 20140314**

Priority  
• US 201361785177 P 20130314  
• US 201461943931 P 20140224  
• US 2014029752 W 20140314

Abstract (en)  
[origin: WO2014153236A1] Disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Also disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Such compounds and methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

IPC 8 full level  
**C12N 15/113** (2010.01)

CPC (source: EP RU US)  
**A61P 25/00** (2017.12 - EP RU); **A61P 25/28** (2017.12 - EP RU); **C12N 15/113** (2013.01 - EP RU US); **C12N 2310/11** (2013.01 - EP US); **C12N 2310/31** (2013.01 - US); **C12N 2310/315** (2013.01 - EP US); **C12N 2310/3181** (2013.01 - EP US); **C12N 2310/32** (2013.01 - US); **C12N 2310/321** (2013.01 - US); **C12N 2310/322** (2013.01 - US); **C12N 2310/3231** (2013.01 - US); **C12N 2310/3233** (2013.01 - US); **C12N 2310/3341** (2013.01 - EP US); **C12N 2310/345** (2013.01 - EP US); **C12N 2310/346** (2013.01 - EP US); **C12N 2310/351** (2013.01 - US); **C12N 2320/33** (2013.01 - EP US)

Cited by  
EP4035659A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2014153236 A1 20140925**; AU 2014236156 A1 20150924; AU 2014236156 B2 20200528; AU 2014236156 C1 20201217; BR 112015022156 A2 20171114; CA 2906119 A1 20140925; CN 105264091 A 20160120; CN 105264091 B 20200228; CN 111254145 A 20200609; EP 2971142 A1 20160120; EP 2971142 A4 20161019; EP 2971142 B1 20200624; EP 3766974 A1 20210120; ES 2807379 T3 20210222; HK 1218659 A1 20170303; IL 241439 A0 20151130; IL 241439 B 20200331; JP 2016513976 A 20160519; JP 2019141097 A 20190829; JP 6629716 B2 20200115; KR 20150130430 A 20151123; MX 2015012621 A 20160531; RU 2015143286 A 20170417; RU 2745324 C2 20210323; US 11155815 B2 20211026; US 2016032285 A1 20160204; US 2018051283 A1 20180222; US 2022243200 A1 20220804; US 9644207 B2 20170509

DOCDB simple family (application)  
**US 2014029752 W 20140314**; AU 2014236156 A 20140314; BR 112015022156 A 20140314; CA 2906119 A 20140314; CN 201480014009 A 20140314; CN 202010078376 A 20140314; EP 14767904 A 20140314; EP 20181501 A 20140314; ES 14767904 T 20140314; HK 16106624 A 20160608; IL 24143915 A 20150910; JP 2016503214 A 20140314; JP 2019089727 A 20190510; KR 20157028169 A 20140314; MX 2015012621 A 20140314; RU 2015143286 A 20140314; US 201414776561 A 20140314; US 201715472110 A 20170328; US 202117481679 A 20210922